Navigation Links
Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
Date:5/7/2008

d's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, cardiovascular disease, and other areas of unmet medical need.

Safe-Harbor

This press release contains forward-looking statements regarding Genzyme's future business plans including, without limitation, statements about the potential uses and benefits of Genz-112638; when final results from the Phase 2 study will be available; and future clinical trial plans and potential uses of the data from such clinical trials. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: the actual timing of the completion of the analysis of clinical study results; Genzyme's ability to accurately understand and predict the outcome and impact of its clinical studies related to Genz-112638; Genzyme's ability to continue to support its clinical and other development efforts related to Genz-112638; the actual efficacy and safety of Genz-112638; the outcome of discussions with regulator
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. WebMD Provides Preliminary First Quarter Results and Updates Financial Guidance for 2008
2. MedCath Provides Preliminary Second Quarter Fiscal 2008 Earnings and Updates Fiscal 2008 Outlook
3. TeamStaff, Inc. Reports Preliminary Second Quarter 2008 Results
4. Longs Reports Preliminary March Retail Drug Store Sales
5. Preliminary Data From Pitt County Memorial Hospital Study Show Benefit of Active Surveillance on Reducing MRSA VAP Rates in Surgical ICU
6. Conseco Reports Preliminary Fourth Quarter and Year-End Results
7. NBTY to Webcast Presentation at Bank of America Consumer Conference: Announces Preliminary Sales and the Repurchase of 6.1 Million Shares
8. Longs Reports Preliminary February Retail Drug Store Sales
9. CRH Medical reports preliminary year end results
10. Sunrise Reports Preliminary Selected Financial and Operating Data for Fourth-Quarter 2007
11. KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... A new study in the American Journal of ... searches reveals a recurring pattern that could be leveraged ... from San Diego State University, the Santa Fe Institute, ... Google searches (searches that included the term healthy and ... U.S. from 2005 to 2012. They found that on ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... to a study published today in PLOS Pathogens ... where malaria is common can mount an immune response ... to avoid repeated bouts of high fever and illness ... their bloodstream. The findings may help researchers develop future ... the malaria parasite. , Each year, approximately 200 million ...
(Date:4/17/2014)... MANHASSET, NY In a review published in the ... MD, president of The Feinstein Institute for Medical Research, ... the medical community,s approach to treating sepsis, ... 200,000 Americans. , Sepsis occurs when molecules released into ... inflammation throughout the body. Inflammation is necessary for maintaining ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... of The Royal Marsden Hospital Manual of Clinical Nursing ... format that organises 15 key chapters into four key ... on areas such as risk management and preparing patients ... from the world-renowned UK centre of excellence, the Manual ...
... HealthDay Reporter , SUNDAY, April 3 (HealthDay News) -- Diabetes ... suggests an increased risk of cancer can be added to that ... had an 8 percent increased risk of developing cancer generally, while ... of prostate cancer were excluded from the calculation. The risk ...
... 4 (HealthDay News) -- Taking aspirin even once per month, ... a marked drop in the risk of developing pancreatic cancer, ... was linked to a 26 percent reduction in the risk ... of heart disease, was associated with an even greater drop ...
... be assessed by examining the epithelial cells found in ... the AACR 102nd Annual Meeting 2011, held April 2-6. ... provide a personalized assessment of breast cancer risk, said ... veterinary and animal sciences at the University of Massachusetts ...
... Prostate cancer is the second leading cause of cancer-related death ... reduced the number of deaths from the disease. By ... risk for aggressive disease or diagnosis at a young age, ... screening approach. For that reason, scientists have been looking for ...
... (March 29, 2011) Medicare coverage and nationwide ... as virtual colonoscopy, has tripled in recent years, according ... Journal of the American College of Radiology ... produce a three-dimensional visualization that permits a thorough and ...
Cached Medicine News:Health News:Patient's journey format drives new edition of vital student nurse manual 2Health News:Patient's journey format drives new edition of vital student nurse manual 3Health News:Add Cancer to Health Risks of Diabetes: Study 2Health News:Add Cancer to Health Risks of Diabetes: Study 3Health News:Monthly Aspirin Use Linked to Lower Pancreatic Cancer Risk 2Health News:Monthly Aspirin Use Linked to Lower Pancreatic Cancer Risk 3Health News:Breast milk may provide a personalized screen of breast cancer risk 2Health News:MicroRNA variations associated with earlier prostate cancer diagnosis in African-American men 2Health News:Nationwide utilization of virtual colonoscopy triples, study suggests 2
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/15/2014)... 15, 2014  A novel wearable injector slightly larger than an ... patients to self-inject prescription drugs in the large doses required ... diseases, autoimmune deficiencies, and genetic disorders.  An ... by 2018, according to analysts.   Many of these drugs will ...
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Dornier Compact Delta lithotripsy system features real value ... systems shock source and C-arm are fully integrated ... risk of misalignment. The therapy head on the ... lateral and horizontal movement and can treat in ...
Used for male external catheterization due to urinary incontinence. The inflatable retention ring secures the catheter and can be easily deflated for removal. Supplied non-sterile. Reusable. Intended...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
Medicine Products: